Abstract
Background: Platelet-Rich (PRP) and Platelet-Poor plasma (PPP) are widely used in research and clinical platforms mainly due to their capacities to enhance cell growth. Although the short half-life (5 days) and the high price of platelet products pose challenges regarding their usage, they maintain the growth regulatory functions for weeks. Thus, we aimed to assess the supplementary values of these products in human CCRF- CEM cancer cells. Mechanistically, we also checked if the PRP/PPP treatment enhances YKL-40 expression as a known protein regulating cell growth.
Methods: The PRP/PPP was prepared from healthy donors using manual stepwise centrifugation and phase separation. The viability of the cells treated with gradient PRP/PPP concentrations (2, 5, 10, and 15%) was measured by the MTT assay. The YKL-40 mRNA and protein levels were assessed using qRT-PCR and western blotting. The data were compared to FBS-treated cells.
Results: Our findings revealed that the cells treated by PRP/PPP not only were morphologically comparable to those treated by FBS but also showed greater viability at the concentrations of 10 and 15%. Moreover, it was shown that PRP/PPP induce cell culture support, at least in part, via inducing YKL-40 expression at both mRNA and protein levels in a time- and dose-dependent manner.
Conclusion: Collectively, by showing cell culture support comparable to FBS, the PRP/PPP might be used as good candidates to supplement the cancer cell culture and overcome concerns regarding the use of FBS as a non-human source in human cancer research.
Keywords: Platelet-rich plasma, platelet-poor plasma, YKL-40, CCRF-CEM, cancer cell, FBS.
Anti-Cancer Agents in Medicinal Chemistry
Title:Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Volume: 21 Issue: 16
Author(s): Mehdi Talebi, Mousa Vatanmakanian, Ali Mirzaei, Yaghoub Barfar, Maryam Hemmatzadeh, Milad A. Nahayati, Kobra Velaei, Asghar Hosseinzadeh, Behruz Yazdanpanah, Yahya Yahyavi, Ako Azimi, Mina Rahmani and Milad Z. Heydarabad*
Affiliation:
- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj,Iran
Keywords: Platelet-rich plasma, platelet-poor plasma, YKL-40, CCRF-CEM, cancer cell, FBS.
Abstract:
Background: Platelet-Rich (PRP) and Platelet-Poor plasma (PPP) are widely used in research and clinical platforms mainly due to their capacities to enhance cell growth. Although the short half-life (5 days) and the high price of platelet products pose challenges regarding their usage, they maintain the growth regulatory functions for weeks. Thus, we aimed to assess the supplementary values of these products in human CCRF- CEM cancer cells. Mechanistically, we also checked if the PRP/PPP treatment enhances YKL-40 expression as a known protein regulating cell growth.
Methods: The PRP/PPP was prepared from healthy donors using manual stepwise centrifugation and phase separation. The viability of the cells treated with gradient PRP/PPP concentrations (2, 5, 10, and 15%) was measured by the MTT assay. The YKL-40 mRNA and protein levels were assessed using qRT-PCR and western blotting. The data were compared to FBS-treated cells.
Results: Our findings revealed that the cells treated by PRP/PPP not only were morphologically comparable to those treated by FBS but also showed greater viability at the concentrations of 10 and 15%. Moreover, it was shown that PRP/PPP induce cell culture support, at least in part, via inducing YKL-40 expression at both mRNA and protein levels in a time- and dose-dependent manner.
Conclusion: Collectively, by showing cell culture support comparable to FBS, the PRP/PPP might be used as good candidates to supplement the cancer cell culture and overcome concerns regarding the use of FBS as a non-human source in human cancer research.
Export Options
About this article
Cite this article as:
Talebi Mehdi , Vatanmakanian Mousa , Mirzaei Ali , Barfar Yaghoub , Hemmatzadeh Maryam , Nahayati A. Milad , Velaei Kobra , Hosseinzadeh Asghar , Yazdanpanah Behruz , Yahyavi Yahya , Azimi Ako , Rahmani Mina and Heydarabad Z. Milad *, Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1871520621999210101225912
DOI https://dx.doi.org/10.2174/1871520621999210101225912 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 3
Current Drug Targets Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Drug Delivery Systems for Chemotherapeutics through Selected Polysaccharidic Vehicles
Current Organic Chemistry Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Current Pharmaceutical Design Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Medical Image Processing Technology for Diagnosing and Treating Cancers
Recent Patents on Biomedical Engineering (Discontinued) Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals